Risk assessment of development and recurrence of urolithiasis in obese patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urolithiasis is one of the most common urologic diseases. One of its risk factors is obesity, which is supported by the meta-analyses. The development of screening programs to predict the risk of urinary stone disease or its recurrence in obese patients is a relevant issue. We searched PubMed for literature published between 2014 and 2024 using the search terms “kidney stone,” “recurrence,” “predictors,” and “obesity.” Eight original studies were included in our study. The most significant predictors of urinary stone disease or its recurrence in obese patients were Ae index, VAI, dietary patterns, and chronic urinary tract infection. However, described models do not take into account all the factors, which are involved in pathogenesis of urinary stone disease in obese patients. Therefore, it is necessary to carry out further research, develop a single standardized diagnostic scale taking into account the results of the aforementioned studies and studied parameters, test and validate this tool for further implementation in clinical practice.

Full Text

Restricted Access

About the authors

V. I. Rudenko

Institute of Urology and Reproductive Health, FGAOU I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: rudenko-vadim@rambler.ru

Ph.D, MD, professor, Chief researcher at the Institute

Russian Federation, Moscow

V. A. Yumasheva

FGAOU I.M. Sechenov First Moscow State Medical University

Email: valentina-jumasheva@rambler.ru
ORCID iD: 0000-0002-4388-5609

student at the Institute of Clinical Medicine named after N. V. Sklifosovskiy

Russian Federation, Moscow

References

  1. Kaprin A.D., Apolikhin O.I., Sivkov A.V., Anokhin N.V., Gadzhiev N.K., Malkhasyan V.A., Akopyan G.N., Prosyannikov M.Yu. The incidence of urolithiasis in the Russian Federation from 2005 to 2020. Experimental and Clinical Urology, 2022;15(2)10-17; https://doi.org/10.29188/2222-8543-2022-15-2-10-17 Russian (Каприн А.Д., Аполихин О.И., Сивков А.В., Анохин Н.В., Гаджиев Н.К., Малхасян В.А., Акопян Г.Н., Просянников М.Ю. Заболеваемость мочекаменной болезнью в Российской Федерации с 2005 по 2020 г. Экспериментальная и клиническая урология. 022;15(2)10-17; https://doi.org/10.29188/2222-8543-2022-15-2-10-17.)
  2. Dedov I.I., Mokrysheva N.G., Mel’nichenko G.A., Troshina E.A., Mazurina N.V., Ershova E.V., Komshilova K.A., Andreeva E.N., Antsiferov M.B., Biriukova E.V., Bordan N.S., Vagapova G.R., Volkova A.R., Volkova N.I., Volynkina A.P., Dzgoeva F.K., Kiseleva T.P., Neimark A.E., Romantsova T.I., Ruiatkina L.A., Suplotova L.A., Khalimov Y.S., Yashkov Y.I. Obesity. Consilium Medicum. 2021;23(4):311–325. doi: 10.26442/20751753.2021.4.200832. Russian (Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В., Ершова Е.В., Комшилова К.А., Андреева Е.Н., Анциферов М.Б., Бирюкова Е.В., Бордан Н.С., Вагапова Г.Р., Волкова А.Р., Волкова Н.И., Волынкина А.П., Дзгоева Ф.Х., Киселева Т.П., Неймарк А.Е., Романцова Т.И., Руяткина Л.А., Суплотова Л.А., Халимов Ю.Ш., Яшков Ю.И. Ожирение. Consilium Medicum. 2021;23(4):311–325. doi: 10.26442/20751753.2021.4.200832.)
  3. Lin B.B., Lin M.E., Huang R.H., Hong Y.K., Lin B.L., He X.J. Dietary and lifestyle factors for primary prevention of nephrolithiasis: A systematic review and meta-analysis. BMC Nephrol. 2020;21:267. doi: 10.1186/s12882-020-01925-3.
  4. Boyd C., Wood K., Whitaker D., Assimos D.G. The influence of metabolic syndrome and its components on the development of nephrolithiasis. Asian J Urol. 2018;5(4):215–222. doi: 10.1016/j.ajur.2018.06.002.
  5. Rahman I.A., Nusaly I.F., Syahrir S., Nusaly H., Mansyur M.A. Association between metabolic syndrome components and the risk of developing nephrolithiasis: A systematic review and bayesian meta-analysis. F1000Res. 2021;10:104. doi: 10.12688/f1000research.28346.1
  6. Bamberger J.N., Rosen D.C., Khusid J.A., Kaplan-Marans E., Gallante B., Kapoor A., Paranjpe I., Atashsokhan D.J., Atallah W.M., Gupta M. The impact of metabolic syndrome components on urinary parameters and risk of stone formation. World J Urol. 2021;39(12):4483–4490. doi: 10.1007/s00345-021-03790-7.
  7. Konstantinova O.V. et.al. Obesity and urolithiasis. Experimental and clinical urology. 2013;2:65-67. Russian (Константинова О.В. и др. Ожирение и мочекаменная болезнь. Экспериментальная и клиническая урология. 2013; 2:65–67).
  8. Lelyavin K.B. et al. Urolithiasis as a new component of “metabolically healthy” obesity. Modern problems of science and education. 2019;4:41-41. Russian (Лелявин К.Б. и др. Мочекаменная болезнь как новый компонент» метаболически здорового» ожирения. Современные проблемы науки и образования. 2019;4:41-41).
  9. Gusakova D.A., Kalinchenko S.Yu., Tyuzikov I.A. Basics of Hormonal and Metabolic Therapy of Urolithiasis. Effective pharmacology. 2018;2:32–39. Russian (Гусакова Д.А., Калинченко С.Ю., Тюзиков И.А. Основы гормонально-метаболической терапии мочекаменной болезни. Эффективная фармакотерапия. 2018;2:32–39).
  10. Bobulescu I.A. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19(4):393–402. doi: 10.1097/MNH.0b013e32833aa4ac.
  11. Witting C., Langman C.B., Assimos D., Baum M.A., Kausz A., Milliner D., Tasian G., Worcester E., Allain M., West M., Knauf F., Lieske J.C. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2021;16(3):487–495. doi: 10.2215/CJN.08000520.
  12. Akarken I., Tarhan H., Ekin R.G., Çakmak Ö., Koç G., İlbey Y.Ö., Zorlu F. Visceral obesity: A new risk factor for stone disease. Can Urol Assoc J. 2015;9(11-12):E795-9. doi: 10.5489/cuaj.3145.
  13. Lama D.J., Safiullah S., Yang A., Okhunov Z., Landman J., Clayman R.V. Three-dimensional evaluation of perirenal fat volume in patients with nephrolithiasis. Urolithiasis. 2018;46(6):535–541. doi: 10.1007/s00240-018-1047-9.
  14. Chen H.W., Lee J.T., Wei P.S., Chen Y.C., Wu J.Y., Lin C.I., Chou Y.H., Juan Y.S., Wu W.J., Kao C.Y. Machine learning models for screening clinically significant nephrolithiasis in overweight and obese populations. World J Urol. 2024;42(1):128. doi: 10.1007/s00345-024-04826-4.
  15. Xia K., Xu Y., Qi Q., Pan J., Yao R., Huang Q., Hao Z. Ae index is an independent predictor of kidney stone recurrence in overweight and obese patients. BMC Urol. 2023;23(1):151. doi: 10.1186/s12894-023-01321-7.
  16. Vaughan L.E., Enders F.T., Lieske J.C., Pais V.M., Rivera M.E., Mehta R.A., Vrtiska T.J., Rule A.D. Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. Mayo Clin Proc. 2019;94(2):202–210. doi: 10.1016/j.mayocp.2018.09.016
  17. Liang D., Liu C., Yang M. The association of visceral adiposity index with the risk of kidney stone and kidney stone recurrence. BMC Nephrol. 2023;24(1):368. doi: 10.1186/s12882-023-03421-w.
  18. Hou B., Shen X., He Q., Chen Y., Xu Y., Chen M., Xi J., Hao Z. Is the visceral adiposity index a potential indicator for the risk of kidney stones? Front Endocrinol (Lausanne). 2022;13:1065520. doi: 10.3389/fendo.2022.1065520.
  19. Ahmed A.E., Abol-Enein H., Awadalla A., Shokeir A.A., El-Shehaby O.A., Harraz A.M. Metabolic stone workup abnormalities are not as important as stone culture in patients with recurrent stones undergoing percutaneous nephrolithotomy. Urolithiasis. 2023;51(1):47. doi: 10.1007/s00240-023-01422-w.
  20. Chewcharat A., Thongprayoon C., Vaughan L.E., Mehta R.A., Schulte P.J., O’Connor H.M., Lieske J.C., Taylor E.N., Rule A.D. Dietary Risk Factors for Incident and Recurrent Symptomatic Kidney Stones. Mayo Clin Proc. 2022;97(8):1437–1448. doi: 10.1016/j.mayocp.2022.04.016.
  21. Leone A., Fernández-Montero A., de la Fuente-Arrillaga C., Martínez-González M.Á., Bertoli S., Battezzati A., Bes-Rastrollo M. Adherence to the Mediterranean Dietary Pattern and Incidence of Nephrolithiasis in the Seguimiento Universidad de Navarra Follow-up (SUN) Cohort. Am J Kidney Dis. 2017;70(6):778–786. doi: 10.1053/j.ajkd.2017.06.027.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media